Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
A M
AM
Cesura
E
E
Borroni
J
J
Gottowik
C
C
Kuhn
P
P
Malherbe
J
J
Martin
J G
JG
Richards
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D001921:Brain / Q000201:enzymology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic / Q000378:metabolism; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D019636:Neurodegenerative Diseases / Q000503:physiopathology; D018384:Oxidative Stress / Q000502:physiology; D010848:Picolinic Acids / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D010848:Picolinic Acids; C059303:lazabemide; D008995:Monoamine Oxidase